Research programme: Bcr-Abl kinase inhibitors - Pfizer Global Research and Development
Alternative Names: PD 166326; PD 180970Latest Information Update: 03 Aug 2009
At a glance
- Originator Pfizer
- Class Antineoplastics; Pyridones; Pyrimidines; Small molecules
- Mechanism of Action Bcr-Abl tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic myeloid leukaemia
Most Recent Events
- 03 Aug 2009 Discontinued - Preclinical for Chronic myeloid leukaemia in USA (unspecified route)
- 15 May 2005 A preclinical study has been added to the cancer pharmacodynamics section
- 18 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the Cancer pharmacodynamics section